EyePoint (EYPT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.09
- Estimate
- -$0.96
- Surprise
- -13.9%
- Revenue (period 2026-06-30)
- $507,000
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
EyePoint (EYPT) reported a wider loss than forecast — diluted EPS of -$1.09 against the -$0.96 estimate (a 13.9% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates EYPT Hold at 5.0/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -13.9% surprise compares with a -13.7% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $25.91 vs price $4.23 — ratio 6.1×). Rejected, falling back to technical TP.
- Market cap $355M below $400M minimum
- Momentum score 2.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.23
- Price target
- $4.86
- Stop
- $3.93
- Upside to target
- +14.9%
Risk check: RSI 23 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
EYPT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $354.6M
- P/E (fwd)
- -1.5
- 52-week range
- $3.95–$19.11
- Off 52-week high
- 77.9%
- RSI (14)
- 23
- Volume vs avg
- 0.38×
- Score today
- 5.0/10